Please login to the form below

Not currently logged in
Email:
Password:

Vertex

This page shows the latest Vertex news and features for those working in and with pharma, biotech and healthcare.

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Vertex has a triple therapy in advanced development, and investors hoped that Proteostatis’ own combination could challenge Vertex. ... This would match the exclusion criteria used in Vertex’s trials, but Y.

Latest news

More from news
Approximately 39 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. " />. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi blame game The Orkambi blame game

    an overly generous deal on Vertex’s first CF drug, Kalydeco, in 2012. ... Vertex, at £850m a year, would go out of business in three to five years.

  • #OrkambiNow? #OrkambiNow?

    Looking to the future, Vertex and other companies will be developing more potent treatments, including gene therapies which could one day cure patients of this terrible disease. ... Fast forward to July 2018, and the row had escalated to the point where

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing technology, is looking to begin a phase I trial with Vertex on a candidate for

More from intelligence
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Cogora

    Reckitt Benckiser. Stallergenes. Sun Pharma. Takeda. ThermoFisher Scientific. Vertex.

  • GCI Health

    Global: Acelity,  Bayer, Janssen, Kite (a Gilead Company), Merck, MSD, Pfizer, Vertex.

  • Warehousing of HCV patients reaches new high

    New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.

  • Random42 Scientific Communication

    Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics